PMID- 35563716
OWN - NLM
STAT- MEDLINE
DCOM- 20220518
LR  - 20220716
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 11
IP  - 9
DP  - 2022 Apr 21
TI  - The Potential Clinical Use of Stem/Progenitor Cells and Organoids in Liver 
      Diseases.
LID - 10.3390/cells11091410 [doi]
LID - 1410
AB  - The liver represents the most important metabolic organ of the human body. It is 
      evident that an imbalance of liver function can lead to several pathological 
      conditions, known as liver failure. Orthotropic liver transplantation (OLT) is 
      currently the most effective and established treatment for end-stage liver 
      diseases and acute liver failure (ALF). Due to several limitations, 
      stem-cell-based therapies are currently being developed as alternative solutions. 
      Stem cells or progenitor cells derived from various sources have emerged as an 
      alternative source of hepatic regeneration. Therefore, hematopoietic stem cells 
      (HSCs), mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), 
      embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are also 
      known to differentiate into hepatocyte-like cells (HPLCs) and liver progenitor 
      cells (LPCs) that can be used in preclinical or clinical studies of liver 
      disease. Furthermore, these cells have been shown to be effective in the 
      development of liver organoids that can be used for disease modeling, drug 
      testing and regenerative medicine. In this review, we aim to discuss the 
      characteristics of stem-cell-based therapies for liver diseases and present the 
      current status and future prospects of using HLCs, LPCs or liver organoids in 
      clinical trials.
FAU - Nikokiraki, Christina
AU  - Nikokiraki C
AD  - Laboratory of Biology, Medical School, National and Kapodistrian University of 
      Athens, 11527 Athens, Greece.
FAU - Psaraki, Adriana
AU  - Psaraki A
AD  - Laboratory of Biology, Medical School, National and Kapodistrian University of 
      Athens, 11527 Athens, Greece.
AD  - Centre of Basic Research, Biomedical Research Foundation of the Academy of Athens 
      (BRFAA), 11527 Athens, Greece.
FAU - Roubelakis, Maria G
AU  - Roubelakis MG
AD  - Laboratory of Biology, Medical School, National and Kapodistrian University of 
      Athens, 11527 Athens, Greece.
AD  - Centre of Basic Research, Biomedical Research Foundation of the Academy of Athens 
      (BRFAA), 11527 Athens, Greece.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220421
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
SB  - IM
MH  - Hepatocytes
MH  - Humans
MH  - *Induced Pluripotent Stem Cells/metabolism
MH  - *Liver Diseases/metabolism/therapy
MH  - Organoids/metabolism
PMC - PMC9101582
OTO - NOTNLM
OT  - EC
OT  - MSCs
OT  - cells
OT  - clinical trials
OT  - hLPCs
OT  - iPSCs
OT  - liver disease
OT  - organoids
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/15 06:00
MHDA- 2022/05/18 06:00
PMCR- 2022/04/21
CRDT- 2022/05/14 01:07
PHST- 2022/03/17 00:00 [received]
PHST- 2022/04/11 00:00 [revised]
PHST- 2022/04/19 00:00 [accepted]
PHST- 2022/05/14 01:07 [entrez]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/04/21 00:00 [pmc-release]
AID - cells11091410 [pii]
AID - cells-11-01410 [pii]
AID - 10.3390/cells11091410 [doi]
PST - epublish
SO  - Cells. 2022 Apr 21;11(9):1410. doi: 10.3390/cells11091410.